Health Studies MN

Within 


Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

3159 Study Matches

Sorting by: Relevance Distance

A Qualitative Approach to Understanding Financial Toxicity in Management of Advanced Prostate Cancer

Understanding Financial Toxicity in Management of Advanced Prostate Cancer from Qualitative Approach

Stephen Boorjian
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308457-H01-RST
22-005013
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age 18 years and older, diagnosed with metastatic prostate cancer.


Exclusion Criteria:
 

  • Have an additional non-prostate cancer diagnosis, have non-metastatic prostate cancer recurrence.

Eligibility last updated 6/7/22. Questions regarding updates should be directed to the study team contact.

 

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Sleep Health, Symptoms, and Functional Performance in People With Inflammatory Bowel Disease (Sleep Health in IBD)

Sleep Health in Inflammatory Bowel Disease

Samantha Conley
All
18 years to 59 years old
This study is NOT accepting healthy volunteers
2022-308479-H01-RST
22-006109
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 and < 60 years.
  • Diagnosed with IBD (Crohn’s disease, ulcerative colitis, or indeterminate colitis).
  • Living in the United States.  


Exclusion Criteria:
 

  • Patients with current ostomies or ileal pouches.
  • Currently in a medication trial for non-FDA approved medication for IBD.
  • Who are blind
  • With current cancer treatment.
  • Pregnant or breastfeeding.
  • Work night or rotating shifts.
  • Diagnosed with severe psychiatric (bipolar disorder, schizophrenia).
  • Neurological conditions affecting the non-dominant hand (due to actigraphy monitoring).
  • Those who do not read and write in English
  • Those without internet access or email address (due to use of internet surveys).
  • Note: We will delay data collection for at least four weeks for those who have had surgery, and 2 weeks for those who have traveled across a time zone or due to daylight savings.

Eligibility last updated 6/9/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Randomized Controlled Trial to Assess the Effect of Music Therapy on the Anxiety of Patients Undergoing Intrauterine Insemination

Assessing the Effect of Music Therapy on the Anxiety of Patients Undergoing Intrauterine Insemination

Alessandra Ainsworth
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2022-308488-H01-RST
22-006147
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • 18 years of age or older undergoing an IUI procedure.
  • IUI must be performed in the REI offices at Mayo Clinic in Rochester.
  • IUI procedure must be on a weekday.
  • IUI procedure is scheduled to be completed by a nurse in the REI Department.


Exclusion Criteria:
 

  • Non-English speaking.
  • IUI procedure on a weekend day.
  • IUI procedure is scheduled with an MD provider (known or expected to be difficult).
  • Planned IUI procedure is cancelled prior to undergoing the procedure.
  • The patient has a documented diagnosis of complete hearing loss or significant hearing impairment in both ears.
  • The patient has previous participated or declined enrollment in the study during a prior IUI procedure.

Eligibility last updated 6/10/22. Questions regarding updates should be directed to the study team contact.

 

Behavioral, Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

AOST2031, A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Stephanie Polites
All
up to 50 years old
Phase 3
This study is NOT accepting healthy volunteers
2022-308493-P01-RST
22-006188
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- Patients must be < 50 years at the time of enrollment.

- Patient must have eligibility confirmed by rapid central imaging review.
 
- Patients must have ≤ 4 nodules per lung consistent with or suspicious for metastases, with at least one of which being ≥ 3 mm and all of which must be ≤ 3 cm size.

- Lung nodules must be considered resectable by either open thoracotomy or thoracoscopic surgery. Determination of resectability is made by the institutional surgeon.

- Patients must have a histological diagnosis of osteosarcoma.

- Patients must have evidence of metastatic lung disease at the time of initial diagnosis, or at time of 1st recurrence following completion of therapy for initially localized disease.

- Patients with newly diagnosed disease must have completed successful gross tumor resection for their primary tumor or surgical local control of primary tumor must be planned to be performed simultaneously with thoracic surgery.

- Newly diagnosed patients must be receiving systemic therapy considered by the treating physician as at least equivalent to methotrexate, doxorubicin and cisplatin (MAP) at the time of enrollment on this study.

- Patients at time of 1st recurrence must have previously completed initial systemic therapy for their primary tumor, considered by the treating physician as at least
equivalent to MAP.


Exclusion Criteria:


- Patients with unresectable primary tumor.

- Patients with pulmonary metastatic lesions that would require anatomic resection (lobectomy or pneumonectomy) or lesions that are defined as "central" (i.e., central
lesion involves or is proximal to segmental bronchi and peripheral is lesion distal to segmental bronchi).

- Patients with pleural or mediastinal based metastatic lesions, or with pleural effusion.

- Patients with disease progression at either the primary or pulmonary metastatic site while on initial therapy.

Note: Once the patient has been enrolled on the study,
additional computed tomography (CT) scans are not anticipated prior to thoracic surgery.

Note: Some variation in nodule size measurements over the course of pre-operative therapy is anticipated and does not qualify for exclusion unless deemed true disease progression by the primary treatment team.

- Patients with evidence of extrapulmonary metastatic disease.

- Patients who received pulmonary surgery for lung metastasis prior to enrollment.

- All patients and/or their parents or legal guardians must sign a written informed consent.

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.

Eligibility last updated 6/10/22. Questions regarding updates should be directed to the study team contact.

Behavioral, Procedure/Surgery
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Development of a droplet digital PCR (ddPCR) assay for the detection of mutant circulating tumor (ct)DNA in patients with uveal melanoma

Detection of Mutant Circulating Tumor (CT)Dna in Uveal Melanoma With Development of a Droplet Digital Pcr (Ddpcr) Assay

Kevin Halling
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308501-H01-RST
22-006011
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients seen in Ophthalmology including ones referred to Oncology with metastatic uveal melanoma


Exclusion Criteria:
 

  • < 18 years of age. 

Eligibility last updated 7/11/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Developing a Platform for Remote at Home Preoperative Evaluation for Obstructive Sleep Apnea

Preoperative Evaluation for Obstructive Sleep Apnea at Home

Amir Lerman
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308528-H01-RST
22-007042
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • ≥ 18 years of age
  • Patients participating in the virtual preoperative evaluation process at Mayo Clinic
  • Undergoing virtual preoperative evaluation
  • Surgery date ≥ 2 weeks from participation
  • STOPBANG score > 4.


Exclusion Criteria:

  • Patients less than age 18 years.
  • Subjects who are not able to provide consent.
  • Patients without the ability to connect to Wi-Fi to transmit home sleep study data.

Eligibility last updated 7/5/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Predicting Acute Respiratory Distress Syndrome (ARDS) and Acute Respiratory Failure (ARF) after Hematopoietic Stem Cell Transplantation (HSCT)

Acute Respiratory Distress Syndrome (ARDS) and Acute Respiratory Failure (ARF) Following Hematopoietic Stem Cell Transplantation

Hemang Yadav
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308529-H01-RST
22-006326
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult (age 18 or greater) patients who consent for enrollment in the study.
  • Have undergone allogeneic HSCT within 100 days or autologous HSCT within 30 days.
  • Not admitted for:
    • Admission only for chemotherapy administration;
    • Control of symptoms related to diarrhea, vomiting, dehydration due to inability to swallow, dysphagia, pain or mucositis. 


Exclusion Criteria:

  • Subject transferred from another institution having already been admitted there for > 24h. This proposal seeks to create a biorepository whose purpose will be to determine mechanism of ARF/ARDS development based on initial hospital course. If a substantial part of a patient’s hospital course preceeds enrollment (and is affected by care received at another institution), we may not get meaningful insights into the ARDS mechanism by enrolling them well into the disease processes that are involved in the pathogenesis of ARDS.
  • ARDS at the time of hospital admission. Since this study is looking at the mechanisms of ARDS development, we would seek to enroll patients before ARDS develops. 
  • Patient’s goals of care are such that ICU transfer (and specifically use of noninvasive or mechanical ventilation) would not be considered. As such, these patients would not be able to develop the outcome of interest (ARDS).

Eligibility last updated 6/17/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Mobile Application Based Lactulose Titration for Prevention of Hepatic Encephalopathy

Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration

Douglas Simonetto
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2022-308598-H01-RST
22-006646
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients over the age of 18 years.
  • Ability to provide written, informed consent.
  • Currently taking lactulose daily for prevention of hepatic encephalopathy.

Exclusion Criteria:

  • Recent change in dosing of opioid medication.
  • Previous Colorectal Surgery.
  • Active diarrheal illness.
  • Lack of smartphone or other smart device at home.

Eligibility last updated 7/8/22. Questions regarding updates should be directed to the study team contact.

 

Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Managing Multiple Seizure Types with Wearable Devices

Development of a Practical, Minimally Invasive Seizure Gauge

Benjamin Brinkmann
All
18 years to 70 years old
Not Applicable
This study is NOT accepting healthy volunteers
2022-308608-H01-RST
22-006702
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

- Patients with epilepsy- scalp EEG or invasive EEG monitoring for clinical care, or an implanted device capable of monitoring brain activity and identifying seizures (e.g.,
NeuroPace RNS, Medtronic PC+S, Medtronic RC+S).
- Pediatric subjects 7 years of age or older.


Exclusion Criteria:

- Cognitive or psychiatric condition rendering patient unable to cooperate with data collection, or manage and recharge smart watch and tablet computer devices.
- Presence of open or healing wounds near monitoring sites (infection risk).

Eligibility last updated 6/23/22. Questions regarding updates should be directed to the study team contact.

 

Device
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate Model 4000 Using Microbubble Resonators to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with Glioblastoma Brain Tumors

Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

Terence Burns
All
18 years to 80 years old
Not Applicable
This study is NOT accepting healthy volunteers
2022-307691-P01-RST
22-003261
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male or female.
  • Between > 18-80 years of age.
  • Able and willing to give informed consent 
  • Subjects with a suspected glioblastoma tumor on pre-operative brain imaging scans.
  • Subjects that are scheduled, or will be scheduled within 4 weeks, for surgical resection or biopsy per standard clinical tumor care.
  • Karnofsky Performance Score > 70.
  • Able to communicate sensations during the Exablate BBBD procedure.


Exclusion Criteria:

  • Tumor originating from the deep midline, thalamus, midbrain, cerebellum or brainstem.
  • Multifocal tumors.
  • MRI or clinical findings of:
    • Active or chronic infection(s) or inflammatory processes;
    • Acute or chronic hemorrhages, specifically any lobar microbleeds, and no siderosis, amyloid angiopathy, or macro-hemorrhages;
    • Intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis.
  • MR non-compatible metallic implants in the skull or the brain or the presence of unknown MR unsafe devices.
  • Significant cardiac disease or unstable hemodynamic status:
    • Documented myocardial infarction within six months of enrollment;
    • Unstable angina on medication;
    • Unstable or worsening congestive heart failure;
    • Left ventricular ejection fraction below the lower limit of normal;
    • History of a hemodynamically unstable cardiac arrhythmia;
    • Cardiac pacemaker;
    • History of hypersensitivity to Perflutren lipid microsphere or its components; e.g., polyethylene glycol.
  • Uncontrolled hypertension (systolic > 180 and diastolic BP > 120 on medication).
  • Unable to discontinue use of anti-coagulant/antiplatelet therapy as per local standard.
  • History of a liver disease, bleeding disorder, coagulopathy or a history of spontaneous hemorrhage or evidence of increased risk of bleeding.
  • Abnormal coagulation profile (Platelets < 80,000), PT (> 14) or PTT (> 36), and INR > 1.3.
  • Known cerebral or systemic vasculopathy.
  • Significant depression and at potential risk of suicide.
  • Known sensitivity/allergy to gadolinium or DEFINITY®.
  •  Active seizures despite medication treatment (defined as > 1 seizure per week) which could be worsened by disruption of the blood brain barrier.
  • Active drug or alcohol disorder which have a higher risk for seizures, infection and/or poor executive functioning.
  • Positive HIV status, which can lead to increased entry of HIV into the brain parenchyma leading to HIV encephalitis.
  • Potential blood-borne infections which can lead to increased entry to brain parenchyma leading to meningitis or brain abscess.
  • Any contraindications to MRI scanning, including:
    • Large subjects not fitting comfortably into the scanner;
    • Difficulty lying supine and still for up to 3 hours in the MRI unit or claustrophobia.
  • Impaired renal function with estimated glomerular filtration rate < 30 mL/min/1.73m^2.
  • Severe Respiratory Illness: chronic pulmonary disorders; e.g.,severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area, subjects with a history of severe drug allergies, asthma or hay fever, and multiple allergies where the benefit/risk of administering Definity® is considered unfavorable by the study physicians in relation to the product labeling for Definity®.
  • Currently in a clinical trial involving an investigational product or non-approved use of a drug or device.
  • Pregnancy or lactation.
Device
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Bipolar Disorder Measures in Clinical Care - Patient Preferences on Measures

Bipolar Disorder Measures in Clinical Care

William Leasure
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307697-P01-RST
22-003286
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • 18 years or older with a clinician diagnosis of bipolar disorder (any bipolar disorder type including bipolar I disorder, bipolar II disorder, cyclothymic disorder, and unspecified bipolar and related disorder).
  • Ability to consent to participation in research. 
  • Patients (n=10) will be recruited from those currently receiving treatment in the included clinics in the Mayo Clinic (Collaborating Institution). 
  • Additionally, stakeholder partners at the Depression and Bipolar Support Alliance will publicize our research study and identify 10-15 individuals with bipolar disorder currently receiving treatment to participate.


Exclusion Criteria:

  • Among participants recruited from the Mayo Clinic, individuals who are not intending to return to care in that system.
  • No exclusion criteria apply to participants recruited from the Depression and Bipolar Support Alliance.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Phase 2, Multicenter, Single Arm, Open Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients With Resectable or Borderline Resectable Pancreatic Ductal Carcinoma (FAPI-46 PDAC)

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

Ajit Goenka
All
18 years and over
Phase 2
This study is NOT accepting healthy volunteers
2022-307706-P01-RST
22-003295
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


1. Pathologically confirmed pancreatic ductal adenocarcinoma

2. Treatment-naïve

3. Staged as resectable or borderline-resectable

4. Planned to undergo surgical resection or to receive neoadjuvant therapy (i.e.,
chemotherapy, radiation therapy, or combination) and subsequent possible surgical
resection

5. Anatomic imaging (e.g., CT, MRI) obtained within ≤ 28 days of consent

6. Age ≥ 18 years

7. Completed informed consent as determined per the IRB of record


Exclusion Criteria:


1. Pregnant as determined by a pregnancy test as per institutional guidelines for
individuals of child-bearing potential

2. Declining to use effective contraceptive methods during the study (for individuals of
child-producing potential)

3. Need for emergent surgery that would be delayed by participation

4. Bacterial, viral, or fungal infections requiring systemic therapy

5. Serious co-morbidities and serious nonmalignant disease (e.g., hydronephrosis, kidney
failure, liver failure, systemic or local inflammatory or autoimmune diseases or other
conditions) that in the opinion of the investigator, physician of record and/or Sofie
could compromise patient safety and/or protocol objectives.

6. Known diagnosis of autoimmune disorders

7. Patients receiving any other investigational agent within the past 28 days

8. Breastfeeding. Note: nursing parents are allowed if the potential participant commits
to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of
the [68Ga]FAPI-46 injection.

9. Known hypersensitivity to any excipients used in [68Ga]FAPI-46:

trace amounts of sodium acetate sodium ascorbate and/or hydrochloric acid

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 10/6/22. Questions regarding updates should be directed to the study team contact.

Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Optical Fusion Trans-Perineal Grid

Optical Fusion Trans-Perineal Grid

David Woodrum
Male
45 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2022-307730-H01-RST
22-003369
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Scheduled for a MR guided biopsy or ablation.
  • Male, 45 years of age or older.
  • One, two, or three tumor suspicious regions identified on multiparametric MRI.
  • Tolerance for anesthesia/sedation.
  • Ability to give informed consent.


Exclusion Criteria:

  • Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI.
  • History of other primary non-skin malignancy within previous three years.
Device
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Testing for Monoclonal Proteins by Blood Spot and Saliva

Monoclonal Proteins by Blood Spot and Saliva

David Murray
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307738-H01-RST
22-003158
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult patients ≥ 18 years old.
  • Diagnosed with plasma cell disorders.


Exclusion Criteria:

  • Children < 18 years old.
  • Pregnant females.

Eligibility last updated 5/2/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

The Effect of Synaquell on Objective Brain Function Measures in Youth Ice Hockey Players

The Effects of Synaquell on Brain Function of Ice Hockey Players

Michael Stuart
Male
13 years to 19 years old
Not Applicable
This study is NOT accepting healthy volunteers
2022-307754-H01-RST
22-003414
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • 18 years of age or greater.
  • Fluent English speakers.
  • Medically cleared to play ice hockey.


Exclusion Criteria:

  • An allergy to the ingredients of Synaquell or Synaquell+ (Magnesium, beta hydroxybutyrate, Glutathione, N-acetyl-L-cysteine, Riboflavin, Magnesium, Leucine,
  • Isoleucine, Valine, Resveratrol, Curcumin Phytosome, Nicotinamide riboside,
  • Docosahexanoic Acid).
  • Clinically documented hearing issues.
  • In-ear hearing aid or cochlear implant.
  • Implanted pacemaker or defibrillator.
  • Metal or plastic implants in skull.
  • Lack of verbal fluency in the English language.
  • History of seizures.
  • Allergy to rubbing alcohol or EEG gel.
  • Unhealthy scalp.

Eligibility last updated 4/11/22. Questions regarding updates should be directed to the study team contact.

Dietary Supplement, Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (CIRCULATE-US)

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Zhaohui Jin
All
18 years and over
Phase 2/3
This study is NOT accepting healthy volunteers
2022-307771-P01-RST
22-003465
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • The patient must have signed and dated an IRB-approved consent form that conforms to federal and institutional guidelines.
  • The patient must be ≥ 18 years old.
  • The patient must have an ECOG performance status of 0 or 1.
  • Patients must have histologically/pathologically confirmed Stage IIIA or Stage IIIB colon adenocarcinoma (T1-3, N1/N1c) with R0 resection accordingly to AJCC 8th edition criteria.
    • NOTE: Patients with pathologic stages II or IIIC colon adenocarcinoma with R0 resection who have a commercially obtained Signatera™ ctDNA+ve assay result post-operatively meeting all timelines and eligibility requirements otherwise, are eligible for enrollment and inclusion in Cohort B.
  • No radiographic evidence of overt metastatic disease within 28 days prior to study entry (CT with IV contrast or MRI imaging is acceptable and must include chest, abdomen, and pelvis).
  • The distal extent of the tumor must be ≥ 12 cm from the anal verge on colonoscopy or above the peritoneal reflection as documented during surgery or on pathology specimen (i.e., excluding rectal adenocarcinomas warranting treatment with chemoradiation).
  • The patient must have had an en bloc complete gross resection of tumor (curative resection). Patients who have had a two-stage surgical procedure, to first provide a decompressive colostomy and then in a later procedure to have the definitive surgical resection, are eligible.
  • The resected tumor specimen and a blood specimen from patients with Stage IIIA or Stage IIIB colon cancer must have central testing for ctDNA using the Signatera™ assay by Natera.
    • NOTE: Patients with stage IIIA or IIIB colon cancer who otherwise meet eligibility criteria and have had ctDNA status checked with the Signatera™ assay as routine care outside of the study, are allowed to be enrolled, and will be retested and placed in either Cohort A or Cohort B depending on the central ctDNA testing result.
    • NOTE: Patients with stage II or IIIC colon cancer who otherwise meet eligibility criteria and have had ctDNA status checked with the Signatera™ assay as routine care outside of the study AND have a ctDNA+ve result, are allowed to be enrolled. Patients will have central ctDNA testing, confirmed to be ctDNA+ve, and placed in Cohort B.
  • Tumor must be documented as microsatellite stable or have intact mismatch repair proteins through CLIA-approved laboratory testing. Patients whose tumors are MSI-H or dMMR are excluded.
  • The treating investigator must deem the patient a candidate for all potential agents used in this trial (5FU, LV, oxaliplatin and irinotecan).
  • The interval between surgery (post-operative Day 7) and study entry must be no more than 60 days.
  • Availability and provision of adequate surgical tumor tissue for molecular diagnostics and confirmatory profiling.
  • Adequate hematologic function within 28 days before study entry defined as follows:
    • Absolute neutrophil count (ANC) must be ≥ 1500/mm^3;
    • Platelet count must be ≥ 100,000/mm^3; and
    • Hemoglobin must be ≥ 9 g/dL;
  • Adequate hepatic function within 28 days before study entry defined as follows:
    • Total bilirubin must be ≤ ULN (upper limit of normal) for the lab; and
    • Alkaline phosphatase must be < 2.5 x ULN for the lab; and
    • AST and ALT must be < 2.5 x ULN for the lab.
  • Adequate renal function within 28 days before study entry defined as serum creatinine ≤ 1.5 x ULN for the lab or measured or calculated creatinine clearance ≥ 50 mL/min using the CockroftGault formula for patients with creatinine levels > 1.5 x ULN for the lab.
  • For Women Creatinine Clearance (mL/min) = (140 – age) x weight (kg) x 0.85 72 x serum creatinine (mg/dL).
  • For Men Creatinine Clearance (mL/min) = (140 – age) x weight (kg) 72 x serum creatinine (mg/dL).
  • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • Pregnancy test (urine or serum according to institutional standard) done within 14 days before study entry must be negative (for women of childbearing potential only).
  • Patients receiving a coumarin-derivative anticoagulant must agree to weekly monitoring of INR if they are randomized to Arm 1 or Arm 3 and receive capecitabine.


Exclusion Criteria:

  • Colon cancer histology other than adenocarcinoma (i.e., neuroendocrine carcinoma, sarcoma, lymphoma, squamous cell carcinoma, etc.).
  • Pathologic, clinical, or radiologic overt evidence of metastatic disease. This includes isolated, distant, or non-contiguous intra-abdominal metastases, even if resected.
  • Tumor-related bowel perforation.
  • History of prior invasive colon malignancy, regardless of disease-free interval.
  • History of bone marrow or solid organ transplantation (regardless of current immunosuppressive therapy needs). Bone grafts, skin grafts, corneal transplants and organ/tissue donation are not exclusionary.
  • Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer (e.g., primary colon adenocarcinomas for which treatment with neoadjuvant chemotherapy and/or radiation is warranted are not permitted).
  • Other invasive malignancy within 5 years before study entry. Exceptions are colonic polyps, non-melanoma skin cancer or any carcinoma-in-situ.
  • Synchronous primary rectal and/ or colon cancers.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
  • Sensory or motor neuropathy ≥ grade 2, according to CTCAE v5.0.
  • Blood transfusion within two weeks before collection of blood for central ctDNA testing.
  • Active seizure disorder uncontrolled by medication.
  • Active or chronic infection requiring systemic therapy.
  • Known homozygous DPD (dihydropyrimidine dehydrogenase) deficiency.
  • Patients known to have Gilbert's Syndrome or homozygosity for UGT1A1*28 polymorphism.
  • Pregnancy or lactation at the time of study entry.
  • Co-morbid illnesses or other concurrent disease that would make the patient inappropriate for entry into this study (i.e., unable to tolerate 6 months of combination chemotherapy or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens or prevent required follow-up).

Inclusion Criteria for Cohort A
•Arm 2 Patients on Second Randomization:

  • Patient must have developed a ctDNA +ve assay during serial monitoring.
  • Patient's willingness to be re-randomized affirmed.
  • The patient must continue to have an ECOG performance status of 0 or 1.
  • No radiographic evidence of overt metastatic disease.
  • Pregnancy test (urine or serum according to institutional standard) done within 14 days before second randomization must be negative (for women of childbearing potential only).
  • Adequate hematologic function within 28 days before second randomization defined as follows:
    • Absolute neutrophil count (ANC) must be ≥ 1500/mm^3;
    • Platelet count must be ≥ 100,000/mm^3; and
    • Hemoglobin must be ≥ 9 g/dL.
  • Adequate hepatic function within 28 days before second randomization defined as follows:
    • Total bilirubin must be ≤ ULN (upper limit of normal) for the lab; and
    • Alkaline phosphatase must be < 2.5 x ULN for the lab; and
    • AST and ALT must be < 2.5 x ULN for the lab.
  • Adequate renal function within 28 days before second randomization defined as serum creatinine ≤ 1.5 x ULN for the lab or measured or calculated creatinine clearance ≥ 50 mL/min using the Cockroft-Gault formula for patients with creatinine levels > 1.5 x ULN for the lab. For Women Creatinine Clearance (mL/min) = (140 – age) x weight (kg) x 0.85 72 x serum creatinine (mg/dL) For Men Creatinine Clearance (mL/min) = (140 – age) x weight (kg) 72 x serum creatinine (mg/dL).

Exclusion Criteria for Cohort A
•Arm 2 patients on Second Randomization:

  • Pregnancy or lactation at the time of second randomization.
  • No longer a candidate for systemic chemotherapy (FOLFOX, CAPOX, and mFOLFIRINOX) in the opinion of the treating investigator.

Eligibility last updated 5/26/22. Questions regarding updates should be directed to the study team contact.

Device, Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Ph.1, Open-Label, Dose Escalation & Expansion for Safety, Tolerability, PK, & Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Zhaohui Jin
All
18 years and over
Phase 1
This study is NOT accepting healthy volunteers
2022-307781-P01-RST
22-003496
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


1. Subjects with histologically or cytologically confirmed advanced / metastatic or surgically unresectable solid tumors whose tumors are refractory to standard therapy.

2. Measurable disease per RECIST v 1.1 (primary or metastatic disease).

3. ECOG performance status 0
•1.

4. Life expectancy of at least 3 months.

5. Age ≥ 18 years.

6. Signed, written Institutional Review Board (IRB) approved informed consent

7. A negative serum pregnancy test (for nonsterile women of child-bearing potential).

8. Acceptable liver function:

- Bilirubin ≤ 1.5 times upper limit of normal;

- AST (SGOT), ALT (SGPT) ≤ 5 times upper limit of normal because of cancer or metastases to the liver.

9. Acceptable renal function, defined as:

o Serum creatinine ≤ 1.5 ULN or Creatinine Clearance ≥ 50 mL/minute.

10. Acceptable hematologic status:

- Hemoglobin ≥ 9 g/dL (a transfusion is allowed if Hemoglobin stays stable thereafter);

- Absolute neutrophil count (ANC) ≥ 1,000 cells/mm^3;

- Platelet count ≥ 100,000 plt/mm^3 x 10^9/ L.

11. Urinalysis with no clinically significant abnormalities.

12. Acceptable coagulation status with partial thromboplastin time (PTT) and International Normalized Ratio (INR) ≤ 1.5 times upper limit of normal unless patient is on anti-coagulants and has stable PTT and PT that are within normal therapeutic range for disease under management.

13. Subject has adequate vitamin D level, as defined by serum total 25-Hydroxyvitamin D [25(OH)D] ≥ 20 to < 60 ng/mL. If subjects are below this threshold, they may receive
vitamin D supplementation se per clinic dosing guidelines and may still be enrolled provided they are started on vitamin D supplementation.

14. Completion of all previous treatments (including surgery, systemic chemotherapy, and radiotherapy) at least 3 weeks before screening.

15. For men and women of child-producing potential, the use of effective contraceptive methods during the study.


Exclusion Criteria:


1. Baseline Q-T corrected interval (QTc) interval of > 470 msec for all subjects calculated using Fridericia's formula.

2. New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/ peripheral artery bypass graft, congestive heart failure within the past 6 months.

3. Known active, uncontrolled infection with HIV or hepatitis B; subjects with hepatitis B allowed if on anti-viral therapy and have a viral load ≤ 500 IU; patients with a history of HIV must be on antiretroviral therapy for at least four weeks and have an HIV viral load ≤ 400 copies/mL, have CD4+ T cell counts ≥ 350 cells/uL and no history of AIDS-defining opportunistic infections within 3 months prior to treatment.

4. Major surgical procedure within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure, during the course of the study.

Note: Placement of a central venous access catheter(s) (e.g., port or similar) is not
considered a major surgical procedure.

5. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.

6. Pregnant or nursing women.

Note: Women of child-bearing potential and men must agree- to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

7. Participation in a clinical study involving administration of an investigational compound within the past 30 days prior to study entry.

8. Unwillingness or inability to comply with procedures required in this protocol.

9. Known allergy or hypersensitivity to the study drug(s) or one of the ingredients in the formulation (e.g., Trehalose dihydrate).

10. Existence of any surgical, medical or laboratory condition that, in the judgment of the clinical investigator, might interfere with the safety, distribution, metabolism
or excretion of the drug.

Eligibility last updated 4/11/22. Questions regarding updates should be directed to the study team contact.

Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

GUt Microbiome In Early and Established Scleroderma Study (The GUMIES study) (GUMMIES)

GUt Microbiome In Early and Established Scleroderma Study

Ashima Makol
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307806-H01-RST
22-003568
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age (years) ≥ 18.
  • Able to provide Written Informed consent.
  • Systemic sclerosis as defined by VEDOSS or ACR/EULAR 2013 Classification criteria.


Exclusion Criteria:

  • Individuals < 18 years.
  • History of IBD (Crohn’s disease or ulcerative colitis), microscopic colitis, or celiac disease.
  • Pregnancy.
  • Prior abdominal surgery (except hernia, fundoplication, C-section, hysterectomy, appendectomy, and cholecystectomy).
  • Prior antibiotic use or new probiotic use in the last 2 weeks.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Pilot study to estimate a reduction of TAVR associated Conduction Disturbance through notification of Cara Monitor during TAVR procedure (CARA 2.0)

Cara CDRM (Conduction Disturbance Risk Monitor) 2.0

Mackram Eleid
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2022-307810-P01-RST
22-003591
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Subject must be ≥ 18 years of age.
  • Subject meets indications for TAVR using approved devices.
  • The study patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
  • Subject is willing to comply with specified follow-up evaluations.
  • Subject meets the legal minimum age to provide Informed Consent based on local regulatory requirements.


Exclusion Criteria:

  • Patient with any implanted or have an indication for treatment with rhythm management device (i.e., pacemaker, Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) at baseline.
  • Any contraindication to the TAVR procedure according to the instructions for use.
  • Subject is less than the legal age of consent, legally incompetent, or otherwise vulnerable.
  • Patients who have a planned treatment with any other investigational device, drug or procedure (excluding registries) during the study period.

Eligibility last updated 6/24/22.   Questions regarding updates should be directed to the study team contact.

Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Bedside Confirmation of Intrauterine Contraception Using Point-of-Care Ultrasound

Using Point-of-Care Ultrasound for Bedside Confirmation of Intrauterine Contraception

Terin Sytsma
All
18 years and over
This study is NOT accepting healthy volunteers
2022-307819-H01-RST
22-003638
Show full eligibility criteria
Hide eligibility criteria

Eligibility last updated [date of initial abstraction or last Mod]. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

68Ga-PSMA-11 PET/CT for Screening Prior to 177Lu-PSMA-617 Therapy

Diagnostic 68Ga-PSMA-11 PET/CT

Geoffrey Johnson
Male
18 years and over
This study is NOT accepting healthy volunteers
2022-307849-P01-RST
22-003732
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • An adult male patient who:
    • Is deemed eligible (or potentially/likely eligible) for PSMA-targeted radionuclide therapy by a Nuclear Medicine Physician or Radiologist in the Nuclear Medicine therapy practice, or by the Prostate Theranostic Tumor Board (PTuB).
    • Is acceptable to be potentially eligible for therapy but have a relative contraindication, such as a minor laboratory abnormality, and be on the list for discussion at the PTuB in the future.
    • Is acceptable to be eligible for PSMA-targeted radionuclide therapy in all regards except for having completed a PSMA-targeted PET scan showing PSMA-positive prostate cancer.
    • Is eligible to be documented in the medical record by the clinical practice.
    • Has not received a 68Ga-PSMA-11 PET/CT or PET/MR, or for whom a repeat 68Ga-PSMA-11 PET/CT exam is needed per the clinical practice to ensure eligibility.
    • Does not otherwise have access to a reimbursable clinical 68Ga-PSMA-11 PET scan.
    • An adult above the age of 18.


Exclusion Criteria:

  • A patient who is:
    • Under the age of 18.
    • Unable to consent per Mayo guidelines.
    • Unable to lay still, or otherwise successfully complete the imaging exam.

Eligibility last updated 4/15/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy. (PIVOINE)

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥ 14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

Robert Pignolo
All
18 years and over
Phase 3
This study is NOT accepting healthy volunteers
2022-308712-P01-RST
22-007027
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- Participant has completed the EOS or End of Treatment Visit of Study PVO-1A-301 or
PVO-1A-202 (PVO-1A-202 Parts C and D correspond to Study PVO-1A-204 in France) and did
not previously withdraw consent from any of the parent studies to be eligible for
Study CLIN-60120-452.

- Participant must be ≥ 14 years of age (aligned with the age of treated participants in
the ongoing parent studies PVO-1A-301 and PVO-1A-202/PVO-1A-204) and qualify as 100%
skeletally mature (if < 18 years, based on assessments carried out at parent EOS Visit;
if ≥ 18 years, automatically considered 100% skeletally mature) or have reached final
adult height based on investigator's assessment, at the time the Study CLIN- 60120-452
informed consent is signed.


Exclusion Criteria:


- History of allergy or hypersensitivity to retinoids, gelatin, lactose (note that
lactose intolerance is not exclusionary) or palovarotene, or unresponsiveness to prior
treatment with palovarotene.

- Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine,
metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease.

- Intercurrent known or suspected non-healed fracture at any location;

- Any other medical condition/clinically significant abnormalities that would expose the
participant to undue risk or interfere with study assessments.

- Amylase or lipase > 2 × above the upper limit of normal (ULN) or with a history of
chronic pancreatitis.

- Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × ULN.

- Fasting triglycerides > 400 mg/dL with or without therapy.

- Suicidal ideation (type 4 or 5) or any suicidal behaviour at the Inclusion Visit as
defined by the Columbia-Suicide Severity Rating Scale (C-SSRS).

- Current use of vitamin A or beta carotene, multivitamins containing vitamin A or beta
carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use
of these products during palovarotene treatment.

- Exposure to synthetic oral retinoids other than palovarotene within 4 weeks of the
Inclusion Visit.

- Concurrent treatment with tetracycline or any tetracycline derivatives due to the
potential increased risk of pseudotumor cerebri.

- Use of concomitant medications that are strong inhibitors or inducers of cytochrome
P450 (CYP450) 3A4 activity; or kinase inhibitors such as imatinib.

- Palovarotene is commercially available in the country where the study is being
conducted.

- Any reason that, in the opinion of the investigator, would lead to the inability of
the participant and/or family to comply with the protocol.

Eligibility last updated 7/1/22. Questions regarding updates should be directed to the study team contact.

Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Exercise Pressor Reflex Pathophysiologic Mechanisms in Human Hypertension

Human Hypertension Exercise Pressor Reflex Pathophysiologic Mechanisms

Joshua Smith
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308879-H01-RST
22-007531
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

Healthy Adults

  • Healthy participants (≥ 18 years of age) will be recruited from the surrounding community.
  • These participants will not have a history of cardiovascular, pulmonary, neurologic, orthopedic, or other diseases affecting the neuromuscular system.
  • Additional inclusion criteria include: age, sex, and body mass index matched to the Human Hypertension (HTN) group and those who are able to engage in exercise (i.e., without significant orthopedic limitations or musculoskeletal disorders limiting their ability to exercise).

Patients with Hypertension

  •  ≥ 18 years of age.
  • Patients with HTN will have a clinical diagnosis of essential HTN and receiving standard pharmacologic therapy for > 3 months.
  • In addition to their primary care physician, Dr. Borlaug, M.D. will provide oversight for all participants throughout the study duration. Patients will be tested while receiving optimized standard pharmacologic optimized therapy. All patients will be managed by their primary care physician or cardiologist with additional review by Dr. Borlaug (Co-Investigator) prior to enrollment to ensure inclusion and exclusion criteria have been satisfied and participation in exercise testing is safe. Additional inclusion criteria include no history of cardiovascular (except for HTN), pulmonary, renal, and/or muscular related abnormalities and those who are able to engage in exercise (i.e., without significant orthopedic limitations or musculoskeletal disorders limiting their ability to exercise).

Patients with Heart Failure:

  • Patients with HF with reduced ejection fraction and HF with preserved ejection fraction will be enrolled for preliminary data for a R01 application.  Patients with HF are expected to have a history of ischemic or idiopathic dilated cardiomyopathy (stable > 6 months with a duration of > 1 year) and New York Heart Association class I-III. Although HF medications may influence multiple physiologic systems, we feel it is important, practical, and safe to study these patients under conditions of optimal care. Concurrent withdrawal of ACE-inhibitor, beta-blocker, digoxin, and/or diuretic therapies would likely be associated with moderate decompensation in a high proportion of patients. Accordingly, the impact of these preliminary data will be generalizable to HF patients receiving standard optimized pharmacologic therapy, consistent with the general community. All patients will be managed by their primary care physician or cardiologist with additional review by Dr. Borlaug (Co-Investigator) prior to enrollment to ensure inclusion and exclusion criteria have been satisfied and participation in exercise testing is safe.


Exclusion Criteria:

  • ≥ 18 years of age.
  • History of dangerous arrhythmias.
  • Body mass index > 35 kg/m^2.
  • Current smokers and/or smoking history > 15 pack years.
  • Pregnant women (testing will be done by research team if requested).
  • Uremia, history of allergy to iodides.
  • Impaired renal function.
  • Creatinine value greater than or equal to 1.3 mg/dL (via clinical record within the past 6 months).
  • Diagnosis of liver disease; or (10) individuals who are not able to engage in exercise.
  • For individuals agreeing to undergo dual energy x-ray absorptiometry (DEXA) scanning for measurement of body composition as part of their study visit, additional exclusion criteria apply: recently administered gastrointestinal contrast or radionuclides; severe degenerative changes or fracture deformity in measurement areas; or inability to attain correct position and/or remain motionless for the measurement period.

Eligibility last updated 7/26/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Quantification of Symptom Relief Following Percutaneous Ablation of the Thyroid

Measuring Symptom Relief After Radiofrequency Ablation of the Thyroid

Thomas Atwell
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308891-H01-RST
22-007581
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • ≥ 18 years of age. 
  • Undergoing Radiofrequency Ablation (RFA) for symptomatic thyroid nodule(s).


Exclusion Criteria:

  • < 18 years of age.
  • Decline to participate in research. 

Eligibility last updated 7/20/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Screening for Peripartum Cardiomyopathies Using Artificial Intelligence (SPEC-AI) in Nigeria (SPEC AI Nigeria)

Screening for Pregnancy Related Heart Failure in Nigeria

Demilade Adedinsewo
Female
18 years to 49 years old
Not Applicable
This study is NOT accepting healthy volunteers
2022-308905-P01-RST
22-000539
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- Currently pregnant or within 12 months postpartum

- Willing and able to provide informed consent


Exclusion Criteria:


- Complex congenital heart disease (single ventricle physiology or significant shunts
with cardiac structural changes)

- Significant conduction abnormalities (ventricular pacing on recorded ECG, pacemaker
dependence, or severely abnormal/bizarre QRS morphology on ECG tracings)

- Unable or unwilling to provide consent

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/20/22. Questions regarding updates should be directed to the study team contact.

Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Remote Mindfulness-Based Physical Activity Intervention for Postmenopausal Women

Remote Mindfulness-Based Physical Activity Intervention for Postmenopausal Women

Emma Fortune Ngufor
Female
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2022-308922-H01-RST
22-007713
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients self-report as being > 1 year postmenopausal.
  • Patients are able to walk without a walking aid.
  • Patients own and know how to operate a smart phone or tablet.
  • Patients are willing and able to complete the activity monitoring.
  • Patients are self-reportedly underactive.


Exclusion Criteria:
 

  • Patients are < 1 year postmenopausal.
  • Patients require a walking aid for daily mobility.
  • Patients do not own a smartphone or table, or are unwilling to use such a device for the purposes of the study.
  • Patients' primary form of exercise is swimming (the activity monitors are not waterproof).
  • Patients are unable or unwilling to complete activity monitoring.
  • Patients are unable to provide informed consent independently.

Eligibility last updated 7/22/22. Questions regarding updates should be directed to the study team contact.

Behavioral, Device
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Development of NGS (next generation sequencing) based circulating tumor DNA (ctDNA) assays for oncology patients with solid tumors

Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors

Gang Zheng
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308976-H01-RST
22-007752
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients seen in Oncology or surgery with a diagnosis of a solid tumor malignancy,.


Exclusion Criteria:
  

  • < 18 years of age. 

Eligibility last updated 7/28/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Pilot Trial of Baked Milk Introduction in Patients with Milk-triggered Eosinophilic Esophagitis

Eosinophilic Esophagitis Pilot Trial of Baked Milk Tolerance

Karthik Ravi
All
18 years to 90 years old
Not Applicable
This study is NOT accepting healthy volunteers
2022-308989-H01-RST
22-007941
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • 18 to 90 years of age
  • Diagnosed with Eosinophilic esophagitis ≥ 15 eosinophils per HPF
  • Going through or completed the six-food elimination diet, with milk only or milk plus one additional food identified as a trigger


Exclusion Criteria:

  • Patients with conditions known to be associated with esophageal eosinophilia, including Crohn’s disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome
  • Topical swallowed steroids within 8 weeks of study enrollment
  • Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy

Eligibility last updated 7/28/22. Questions regarding updates should be directed to the study team contact.

 

Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Characteristics and Management of Acute Kidney Injury in Hospitalized Patients With Cirrhosis: a Multicenter Intercontinental Observational Prospective Study: The International Club of Ascites GLOBAL AKI Project (GLOBAL-AKI)

International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

Douglas Simonetto
All
18 years and over
This study is NOT accepting healthy volunteers
2022-308993-P01-RST
22-007946
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

1. Patients with cirrhosis admitted to hospital for the treatment of a complication of liver disease (ascites, gastrointestinal bleeding, hepatic encephalopathy, bacterial infections, jaundice, etc.).


Exclusion Criteria:

1. Age < 18 years old.

2. Pregnancy.

3. Hepatocellular carcinoma outside Milan criteria (i.e., a single lesion < 5 cm or multiple lesions [maximum of three], the largest of which measures ≤ 3 cm).

4. Extrahepatic malignancy other than non-melanoma skin cancer within last 5 years.

5. Previously known severe extrahepatic diseases (e.g., chronic renal failure requiring hemodialysis, severe congestive heart disease [NYHA class ≥ 3]; severe chronic obstructive pulmonary disease [GOLD class ≥ 3], psychiatric disorders).

6. Previous solid organ transplantation.

7. HIV infection with CD4 ≤ 250/µL.

8. Patients who cannot provide prior informed consent and no legal surrogate decision maker.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 7/28/22. Questions regarding updates should be directed to the study team contact.

I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Stories for Change: Cancer Prevention

Cancer Prevention: Stories for Change in Hispanic Community

Irene Sia
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2022-309050-H01-RST
22-008177
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Hispanic adults (age 18 or older).
  • Speak Spanish fluently.
  • Identify as a survivor or co-survivor of breast, cervical, or colorectal cancer.
  • Have received all the recommended COVID-19 vaccinations for their age group (we will be in close quarters during the DST workshop and want to protect any participants who may be immunocompromised after receiving cancer treatment).


Exclusion Criteria:
 

  • People younger than 18 years old.
  • Non-Hispanic individuals.
  • Hispanic individuals who do NOT speak Spanish.
  • Individuals who do NOT identify as a survivor or co-survivor of breast, cervical, or colorectal cancer.
  • Individuals who have not received a COVID-19 vaccination.

Eligibility last updated 8/2/22. Questions regarding updates should be directed to the study team contact

Behavioral
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN